As of the latest Form 4 filed Jun 26, 2026.
What Krystal Biotech Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 45 most recent filings for KRYS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | 2026-06-25 | Thomas John Charles EVP, General Counsel | SSale | −1.00K | $347.27 | $347K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Thomas John Charles, EVP, General Counsel | MExercise | +1.00K | $179.25 | $179K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma President, R&D | SSale | −240.00 | $311.65 | $74.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −2.04K | $310.94 | $634K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −2.80K | $309.95 | $868K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −3.80K | $308.89 | $1.17M | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −12.7K | $307.81 | $3.92M | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −1.35K | $307.09 | $414K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −480.00 | $305.87 | $147K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −400.00 | $304.89 | $122K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −247.00 | $303.17 | $74.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −593.00 | $302.25 | $179K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Suma, President, R&D | SSale | −320.00 | $300.75 | $96.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S President and CEO | SSale | −40.00 | $312.23 | $12.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −964.00 | $311.36 | $300K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −2.65K | $310.43 | $823K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −2.78K | $309.49 | $862K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −4.83K | $308.47 | $1.49M | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −11.5K | $307.68 | $3.53M | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −589.00 | $306.33 | $180K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −544.00 | $304.81 | $166K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −176.00 | $303.17 | $53.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −640.00 | $302.24 | $193K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Krishnan Krish S, President and CEO | SSale | −320.00 | $300.75 | $96.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | Thomas John Charles EVP, General Counsel | SSale | −642.00 | $302.03 | $194K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma President, R&D | SSale | −1.70K | $266.42 | $453K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −6.00K | $265.16 | $1.59M | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −4.85K | $264.64 | $1.28M | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −2.25K | $263.58 | $593K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −1.94K | $262.35 | $508K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −2.93K | $261.41 | $766K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −3.67K | $260.37 | $955K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −668.00 | $259.61 | $173K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −589.00 | $258.54 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Suma, President, R&D | SSale | −407.00 | $257.32 | $105K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S President and CEO | SSale | −920.00 | $266.56 | $245K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −2.44K | $265.59 | $648K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −8.80K | $264.85 | $2.33M | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −2.04K | $263.70 | $539K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −2.38K | $262.44 | $625K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −2.96K | $261.41 | $774K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −3.13K | $260.49 | $815K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −1.38K | $259.87 | $358K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −470.00 | $258.38 | $121K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Krishnan Krish S, President and CEO | SSale | −483.00 | $257.31 | $124K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also KRYS’s full analysis or the market-wide insider trading feed. The tabs above jump to KRYS’s other SEC data.
Source: SEC Form 4 filings for KRYS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.